MENU
GNOM
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

GNOM stock forecast, quote, news & analysis

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index")... Show more

Category: #Health
GNOM
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for GNOM with price predictions
Jun 09, 2026

GNOM in upward trend: price rose above 50-day moving average on May 20, 2026

GNOM moved above its 50-day moving average on May 20, 2026 date and that indicates a change from a downward trend to an upward trend. In of 52 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 21, 2026. You may want to consider a long position or call options on GNOM as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GNOM just turned positive on May 26, 2026. Looking at past instances where GNOM's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GNOM advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GNOM moved out of overbought territory on June 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 70 cases where GNOM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GNOM broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GNOM entered a downward trend on May 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Gilead Sciences (NASDAQ:GILD), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Market Cap

The average market capitalization across the Global X Genomics & Biotechnology ETF ETF is 14.53B. The market cap for tickers in the group ranges from 50.13M to 155.82B. GILD holds the highest valuation in this group at 155.82B. The lowest valued company is SGMO at 50.13M.

High and low price notable news

The average weekly price growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was 6%. For the same ETF, the average monthly price growth was 44%, and the average quarterly price growth was 91%. TECH experienced the highest price growth at 9%, while CRBU experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was -17%. For the same stocks of the ETF, the average monthly volume growth was -29% and the average quarterly volume growth was 9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 66
Price Growth Rating: 55
SMR Rating: 100
Profit Risk Rating: 91
Seasonality Score: 44 (-100 ... +100)
View a ticker or compare two or three
GNOM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Global X Funds600 Lexington Avenue, 20th FloorNew York
Phone
+1 8884938631
Web
www.globalxfunds.com
GNOM in upward trend: price rose above 50-day moving average on May 20, 2026